Auxly Cannabis Sees Revenue Grow 21% Sequentially, Losses Narrow

Despite continued growth in topline revenue, positive net income continues to evade Auxly Cannabis (TSX: XLY). The firm this morning posted its second quarter financing results, indicated that its revenue had climbed a substantial 20.8% on a sequential basis.

Revenues for the second quarter came in at $27.3 million, an improvement over the $22.6 million reported in the first quarter of the year. Cost of sales however came in at $20.6 million, with inventory impairments adding a further $1.8 million to production costs, resulting in a gross profit of $5.0 million before fair value adjustments.

“With an increasingly competitive market, we have been able to maintain our position as the #1 LP in cannabis 2.0 sales, driven by our leadership position in the vapour category where we ended the first half of the year as the #1 LP in the category with over 17% share of market. We successfully increased revenues and gross profits during the quarter while maintaining our SG&A spending largely flat,” commented CEO Hugo Alves.

At the same time, expenses nearly matched net revenues at $25.1 million, lead by SG&A expenses of $12.9 million and interest and accretion expenses of $5.3 million. Other income of $0.9 million attempted to offset some of those expenses to little effect.

Overall, the company posted a net loss of $14.3 million for the quarter, while adjusted EBITDA came in at negative $4.0 million. Comparatively, the firm had a net loss of $39.8 million in the first quarter, and negative adjusted EBITDA of $5.6 million.

Cash and cash equivalents meanwhile came in at $20.4 million, versus $16.3 million at the end of the first quarter, with total current assets sitting at $118.3 million. Accounts payable meanwhile presently sits at $32.0 million, while total current liabilities amounts to $46.9 million.

“As we enter the second half of 2022, we will continue to focus on cost control and margin enhancement through continue process improvements and investments in automation to further support our key objective of Adjusted EBITDA profitability in 2022,” said Alves.

Auxly Cannabis last traded at $0.075 on the TSX.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Goliath Resources Hits 10.60 g/t Gold Over 22.82 Metres, Highest Grade Results In Third Distinct Rock Package At Surebet Discovery

Four Countries Control the Fertilizer That Feeds the World | Sage Potash

$10,000 Gold Is Just A Question of Time | Florian Grummes

Recommended

Antimony Resources Drills 5.27% Sb Over 4.95 Metres In Latest Results

Nord Precious Metals Identifies 29 Veins At Castle East Following 3D Modeling

Related News

Auxly Cannabis Sees 2021 Revenue Growth Of 79%, Still EBITDA Negative

Auxly Cannabis (TSX: XLY) was amongst the numerous names that reported their fourth quarter and...

Thursday, March 31, 2022, 10:02:31 AM

Auxly Cannabis Clarifies FSD Pharma Joint Venture Termination

Auxly Cannabis (TSXV: XLY, OTCMKTS: CBWTF) clarified yesterday the termination of its joint venture with...

Friday, February 8, 2019, 02:00:35 PM

Auxly Reports Revenues of $2.31 million for Second Quarter

Auxly Cannabis (TSXV: XLY) reported its second quarter earnings for fiscal year 2019, indicating the...

Friday, August 16, 2019, 09:53:37 AM

Auxly Cannabis Receives $123 Million Cash Injection From Imperial Brands

Auxly Cannabis Group (TSXV: XLY) announced this morning that it would be receiving a significant...

Thursday, July 25, 2019, 09:54:11 AM

Auxly Cannabis Sees Imperial Brands Grant Two Year Extension To Debentures

Auxly Cannabis (TSXV: XLY) has managed to obtain an extension to certain outstanding debts held...

Monday, April 19, 2021, 08:37:19 AM